PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1358056
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1358056
Global tissue plasminogen activator market is estimated to be valued at US$ 2.58 Bn in 2023, and is expected to exhibit a CAGR of 5.2% during the forecast period (2023-2030).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 2.58 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 5.20% | 2030 Value Projection: | US$ 3.68 Bn |
Tissue plasminogen activator, also known as tissue-type plasminogen activator (tPA), is a serine protease that is present in endothelial cells, the cells that line blood arteries, and is involved in the process of breaking down blood clots (fibrinolysis). Plasminogen is transformed into plasmin by the tPA enzyme. tPA can be employed in studies on embolic or thrombotic stroke.
tPA may be produced by using recombinant biotechnology methods. This kind of tPA is known as recombinant tissue plasminogen activator (rtPA). t-PA is a proteolytic enzyme present in blood and tissues. The primary physiological function of t-PA is the production of plasmin that can break blood clots in the vasculature.
Increasing prevalence of ischemic stroke is expected to drive the market growth over frecast period as tissue-type plasminogen activator (tPA) is used to treat ischemic stroke. For instance, in 2022, according to World Stroke Organization (WSO), there are over 7.6 million new ischemic strokes each year worlwide. Ischemic strokes accounted for more than 62% of incident strokes worldwide in 2019. People aged 15 to 49 account for nearly 11% of all ischemic strokes each year.
Moreover, according to the 2022 report from the American Heart Association, there were approximately 244.1 million individuals globally living with ischemic heart disease (IHD) in the year 2020. This condition was found to be more prevalent among males, with approximately 141.0 million affected, compared to females, where the estimated number of affected individuals was 103.1 million.
Key features of the study: